Quarterly report pursuant to Section 13 or 15(d)

Deerfield Obligation

v3.10.0.1
Deerfield Obligation
6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Deerfield Obligation
8. Deerfield Obligation
 
In relation to the Company's acquisition of the Avadel pediatric products on February 16, 2018, the Company assumed an obligation that Avadel had to Deerfield CSF, (the "Deerfield Obligation"). Beginning in July 2018 through October 2020, the Company will pay a quarterly payment of $262,500 to Deerfield. In January 2021, a balloon payment of $15,250,000 is due. On the acquisition date, the Company determined the fair value of these payments to be $15,075,000 using a market participant's estimated cost of debt. Management performed a credit risk analysis that determined the Company's credit rating to be B to BB plus the yield on a ten-year treasury security. The difference between the gross value and fair value of these payments will be recorded as interest expense in the Company's condensed consolidated statements of operations through January 2021 using the effective interest method. Interest expense for the three months ended June 30, 2018 was $242,407. Interest expense for the six months ended June 30, 2018 was $351,566. The amounts due within the next year are included in current portion of long-term debt on the Company's condensed consolidated balance sheets. The amounts due in greater than one year are included in long-term debt, net of current portion, on the Company's condensed consolidated balance sheets. The Deerfield Obligation was $15.4 million as of June 30, 2018, of which $1.1 million is recorded as a current liability.